Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 5Withdrawn 3Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × futuximab × Clear all
NCT03717038 2019-02-04

Sym004 Versus TAS-102 in Patients With mCRC

Symphogen A/S

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Symphogen A/S

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02965417 2017-02-01

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Symphogen A/S

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡